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 Abstract 
 Background : Antiepileptic drugs (AEDs) are commonly 
used in the treatment of epilepsy, psychiatric diseases 
and pain disorders. Several of these drugs influence blood 
levels of folate and vitamin B12 and, consequently, homo-
cysteine. This may be relevant for AED effects and side 
effects. However, not only folate and vitamin B12, but also 
genetic variants modify homocysteine metabolism. Here, 
we aimed to determine whether there is a pharmacoge-
netic interaction between folate, vitamin B12 and genetic 
variants and homocysteine plasma level in AED-treated 
patients. 
 Methods : In this mono-center study, we measured homo-
cysteine, folate and vitamin B12 plasma levels in a popu-
lation of 498 AED-treated adult patients with epilepsy. In 
addition, we analyzed the genotypes of seven common 
genetic variants of homocysteine metabolism: methyl-
enetetrahydrofolate reductase ( MTHFR ) c.677C > T and 
c.1298A > C, methionine synthase ( MTR ) c.2756A > G, dihy-
drofolate reductase ( DHFR ) c.594 + 59del19bp, cystathio-
nine  β -synthase ( CBS ) c.844_855ins68, transcobalamin 
2 ( TC2 ) c.776C > G and methionine synthase reductase 
( MTRR ) c.66G > A. 
 Results : On multivariate logistic regression, folate and 
vitamin B12 levels, but none of the genetic variants, were 
predictive for homocysteine levels. 
 Conclusions : These data suggest that, in AED-treated 
patients, folate and vitamin B12 play important roles in 
the development of hyperhomocysteinemia, whereas 
genetic variants of homocysteine metabolism do not and 
thus do not contribute to the risk of developing hyper-
homocysteinemia during AED treatment. 
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 Introduction 
 Antiepileptic drugs (AEDs) are widely used to treat epileptic 
seizures, psychiatric diseases and pain syndromes. Several 
side effects and risks limit the usage of AEDs. A character-
istic of several AEDs is a reduction of folate and vitamin B12 
serum levels accompanied by an increase of homocysteine 
plasma levels [ 1 – 4 ]. A mild to moderate increase in homo-
cysteine plasma levels has been firmly established as an 
independent risk factor for cardiovascular [ 5 ,  6 ] and neu-
rodegenerative [ 7 – 9 ] diseases in the general population. 
Epidemiologic studies show that patients with epilepsy 
have an increased risk for ischemic heart disease, fatal 
cardiovascular outcome and neurodegenerative diseases 
such as dementia and Parkinson ’ s disease, which may be 
attributed to hyperhomocysteinemia [ 10 – 13 ]. In addition, 
increased homocysteine plasma levels potentially lead to 
the aggravation of seizures, as indicated by experimental 
data [ 14 ] and in patients with alcohol withdrawal seizures 
[ 15 ]. Therefore, the effect of AEDs on vitamin and homo-
cysteine metabolism and ultimately on cardiovascular 
and neurological disease is a relevant research area in the 
patient population receiving chronic AED treatment. 
 Not only vitamin status, but also genetic variants may 
modify folate, vitamin B12 and homocysteine metabolism 
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( Figure 1 ) [ 16 ]. Several studies have reported that eleva-
tion of homocysteine plasma levels during AED treatment 
is enhanced by the presence of genetic risk factors such as 
the presence of the T allele of the common methylenetet-
rahydrofolate reductase ( MTHFR ) c.677C > T polymorphism 
[ 18 – 22 ]. However, these studies are limited due to their 
small study populations and the small number of genetic 
variants of homocysteine metabolism tested. In this study, 
we investigated whether there is a relevant pharmacoge-
netic relationship between folate, vitamin B12 and seven 
genetic variants of homocysteine metabolism and homo-
cysteine plasma level in 498 AED-treated patients. 
 Materials and methods 
 Patients 
 Inclusion criteria: This mono-center study included adult se-
rial in- and out-patients with epilepsy seen in the Department for 
 Epileptology of the University Hospital Bonn, Germany. The patients 
were treated with various commonly used AEDs in mono- or com-
bined therapy [ 4 ]. 
 Exclusion criteria: Patients with conditions that could potential-
ly infl uence folate, vitamin B12 or homocysteine plasma levels, such 
as renal insuffi  ciency, atrophic gastritis and alcohol or drug abuse, 
were excluded from the study. Patients who were taking vitamin sup-
plements were also excluded. 
 This study was approved by the Local Ethics Committee. All pa-
tients gave their informed written consent. 
 Laboratory investigations 
 Serum concentrations of vitamin B12 and folate were measured by 
means of a competitive chemiluminescent immunoassay with an Ac-
cess ™ Immunoassay System (Beckman Coulter, Krefeld, Germany). 
The intra-assay coeffi  cient of variation of the folate assay was 3.1% 
(mean: 14.1 nmol/L; n = 20); the inter-assay coeffi  cient of variation 
was 3.6% (mean: 14.3 nmol/L; n = 20). The intra-assay coeffi  cient of 
variation of the vitamin B12 assay was 3.8% (mean: 487 pmol/mL; 
n = 20); the inter-assay coeffi  cient was 4.2% (mean: 492 pmol/L; 
n = 20). Homocysteine was determined by fully automated particle-
enhanced immunonephelometry with a BN II System (Siemens 
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 Figure 1   Homocysteine metabolism. 
The sulfur-containing amino acid methionine is activated to S-adenosylmethionine (SAM), which is a ubiquitous methyl group donor. The 
degradation product of SAM is S-adenosylhomocysteine (SAH), which is hydrolyzed to homocysteine. Homocysteine can be remethylated 
to methionine and SAM via methionine synthase (MTR), which depends on derivatives of folate and vitamin B12 as cofactors. Lack of these 
vitamins is a common cause of hyperhomocysteinemia [ 17 ]. The folate derivative is synthesized by methylenetetrahydrofolate reductase 
(MTHFR) and dihydrofolate reductase (DHFR), and the derivative of vitamin B12 is transported by transcobalamin 2 (Tc2). Alternatively, 
homocysteine can be transsulfurated by vitamin B6 dependent cystathionine  β -synthase (CBS) and cystathionine gamma-lyase (CGL) to 
cysteine as a component of glutathione. Due to the existence of several functional variants in the genes involved in homocysteine metabo-
lism, and to differences in dietary vitamin and amino acid uptake, disorders of homocysteine metabolism exhibit marked inter-individual 
differences.
Semmler et al.: Antiepileptic drugs, genetic variants and homocysteine      667
Healthcare Diagnostics, Eschborn, Germany) by enzymatic conver-
sion to S-adenosylhomocysteine. The intra-assay coeffi  cient of vari-
ation of the homocysteine assay was 3.4% (mean: 11  μ mol/L, n = 20); 
the inter-assay coeffi  cient was 5.6% (mean:  μ mol/L, n = 20) [ 1 ]. 
 Genomic DNA prepared from peripheral leukocytes was used for 
genotyping by PCR amplifi cation and, where applicable, subsequent 
restriction analysis of the seven genetic variants of homocysteine me-
tabolism ( Table 1 ). 
 Statistical analysis 
 Plasma levels of homocysteine plasma and serum levels of folate and 
vitamin B12 were tested for normal distribution by the Kolmogorov-
Smirnov test. The distribution of genotypes was tested with a chi-
square goodness-of-fi t test (Pearson). Bivariate Pearson ’ s correlation 
was used to analyze correlations between folate, vitamin B12 and 
homocysteine levels. To analyze associations between the diff erent 
genotypes and folate and vitamin B12 levels and folate and vitamin 
B12 tertiles, univariate analysis of variance (ANOVA) and Pearson ’ s 
 χ 2 -tests were used, respectively. To analyze independent associations 
with homocysteine plasma level as the primary parameter of inter-
est, we applied multivariate linear regression analysis with homo-
cysteine plasma level as the dependent variable and with the genetic 
variants, folate and vitamin B12 plasma levels and age and sex as 
covariables. One-way ANOVA was used for exploratory comparison 
of homocysteine plasma levels between patients with the  MTHFR 
c.677C > T genotype treated with either carbamazepine or phenytoin. 
The threshold was defi ned as two-sided  α = 0.05. 
 Results 
 Demographic, biochemical and genetic data from the 498 
patients (51.4% male) enrolled in this study are shown 
in  Table 2 . Genotyping succeeded for all genetic vari-
ants. Genotype distributions did not deviate from Hardy-
Weinberg equilibrium. Homocysteine plasma levels as 
well as folate and vitamin B12 serum levels were within 
the normal distribution. Thus, the data were not log-trans-
formed. First, we evaluated the relationships between 
folate and vitamin B12 levels and homocysteine level by uni-
variate analysis and found negative correlations between 
homocysteine and folate (Pearson = − 0.334; p < 0.001) 
and homocysteine and vitamin B12 (Pearson = − 0.236; 
p = 0.001). Therefore, we included folate and vitamin B12 
plasma levels along with age, sex and all seven genetic 
variants as covariables for multivariate analysis of inde-
pendent associations with homocysteine plasma level as 
the dependent variable. The associations between folate 
and vitamin B12 with homocysteine level were confirmed, 
but none of the genotypes showed an association with 
homocysteine level ( Table 3 ). In addition, none of the gen-
otypes was associated with folate or vitamin B12 serum 
level (data not shown). However,  MTHFR c.677C > T was 
associated with folate tertiles; i.e., patients with the TT 
genotype had a higher likelihood of having folate serum 
 Demographic/biochemical 
data 
 Mean  SD  
 Age, years  40.0  14.0  
 Vitamin B12, pmol/L  268  137  
 Folate, nmol/L  11.6  7.9  
 Homocysteine,  μ mol/L  15.5  8.6  
 Sex, n (%)  Male  Female  
  256 (51.4%)  242 (48.6%)  
 Frequency of genotype    
 MTHFR c.677C > T  CC  CT  TT 
 n (%)  219 (44%)  224 (45%)  55 (11%) 
 MTHFR c.1298A > C  AA  AC  CC 
 n (%)  214 (43%)  229 (46%)  55 (11%) 
 MTR c.2756A > G  AA  AG  GG 
 n (%)  349 (70%)  134 (27%)  15 (3%) 
 TC2 c.776 C > G  CC  CG  GG 
 n (%)  149 (30%)  229 (46%)  120 (24%) 
 DHFR c.594 + 59del19  dd  di  ii 
 n (%)  90 (18%)  244 (49%)  164 (33%) 
 CBS c.844_855ins68  dd  di  ii 
 n (%)  418 (84%)  75 (15%)  5 (1%) 
 MTRR G > A  GG  GA  AA 
 n (%)  100 (20%)  259 (52%)  139 (28%) 
 Table 2   Demographic and biochemical data and frequency of 
genotypes in the study population (n = 498). 
 All genotypes were in Hardy-Weinberg equilibrium. SD, standard 
deviation. 
 Genetic variant  Peptide variant  rs/Genbank no.  Reference 
 MTHFR c.677C > T  A222V  rs1801133  [ 23 ] 
 MTHFR c.1298A > C  E429A  rs1801131  [ 24 ] 
 MTR c.2756A > G  D919G  rs1805087  [ 25 ] 
 Tc2 c.776C > G  P259R  rs1801198  [ 26 ] 
 DHFR c.594 + 59del19bp  Change of transcription level?  NM_000791.3  [ 27 ] 
 CBS c.844_855ins68  Change of transcription level?  S78267.1  [ 28 ] 
 MTRR c.66G > A  M22I  rs1801394  [ 29 ] 
 Table 1   The genetic variants of homocysteine metabolism analyzed in this study. 
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levels in the lowest tertile ( χ 2 = 3.1; p = 0.011). Next, we con-
ducted an exploratory analysis of patients who received 
carbamazepine or phenytoin monotherapy (n = 76), 
looking for an association between  MTHFR c.677C > T and 
homocysteine plasma level, which has been reported by 
previous studies [ 18 – 22 ]. However, we observed no signifi-
cant differences (ANOVA: F = 2.5; p = 0.091). 
 Discussion 
 In our study cohort of 498 AED-treated epilepsy patients, 
we observed no associations between any of seven genetic 
variants of homocysteine metabolism and homocysteine 
plasma level. Only folate and vitamin B12 serum levels 
were associated with homocysteine plasma level. This 
indicates that hyperhomocysteinemia during chronic AED 
treatment is driven by decreased folate and vitamin B12 
levels and not by a pharmacogenetic risk profile. 
 This is surprising, because genetic variants of homo-
cysteine metabolism are firmly established risk factors for 
hyperhomocysteinemia in the general population; e.g., 
 MTHFR c.677C > T influences homocysteine plasma levels, 
with differences of approximately 2  μ mol/L (15% – 20%) 
between homozygous carriers of the wild-type C versus the 
mutant T allele [ 23 ]. In addition, the T variant also influ-
ences folate metabolism, resulting in lower total folate 
levels [ 30 ]. In our study, the association with folate level 
was weak and was significant only with folate tertiles. We 
speculate that the effects of the AEDs on folate and homo-
cysteine levels overcame the weaker effects of the genetic 
variants in our patient population. This is in contrast to 
previous studies describing genetic risk factors for hyper-
homocysteinemia during AED treatment  – principally the 
T allele of  MTHFR c.677 C > T and the C allele of  MTHFR 
c.1298A > C [ 18 – 22 ]  – and may be explained by the differing 
study populations. For example, Yoo et al. described an 
association between the TT genotype of  MTHFR c.677 C > T 
and higher homocysteine plasma levels in AED-treated 
patients [ 21 ]. However, the subjects enrolled in that study 
were from Korea and were younger (27.5 ± 8.5 years) and 
had lower mean homocysteine plasma levels (11.2 ± 1.5 
 μ mol/L), higher folate (18.8 ± 10.2 nmol/L) and higher 
vitamin B12 serum levels (630 ± 252 pmol/L) than the 
patients in our study ( Table 2 ). Thus, we cannot exclude 
the possibility that the small subgroup sizes of that study 
or demographic differences between the populations con-
tributed to the conflicting results. 
 In conclusion, patients undergoing chronic AED treat-
ment should be screened for folate, vitamin B12 deficiency 
and hyperhomocysteinemia on a regular basis and any 
vitamin deficiency should be corrected when necessary 
[ 4 ]. Screening for genetic variants is not feasible for the 
detection of patients at risk and should not be included in 
the clinical work-up. 
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